Glucotrack (GCTK) EBITDA (2010 - 2025)

Glucotrack has disclosed EBITDA across 15 years of filings, most recently posting -$3.7 million for Q4 2025.

• Quarterly EBITDA rose 63.69% year-over-year to -$3.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$19.3 million (up 14.33% YoY) and the FY2025 annual result came in at -$19.3 million, up 14.33% from the prior year.
• EBITDA rose to -$3.7 million in Q4 2025, from -$4.2 million in the prior quarter.
• Over five years, EBITDA peaked at $6.7 million in Q4 2021 and troughed at -$10.1 million in Q4 2024.
• A 5-year average of -$2.4 million and a median of -$1.8 million in 2022 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2021 — EBITDA jumped 790.87% — and 2024, when it tumbled 313.95%.
• Tracing GCTK's EBITDA over 5 years: stood at $6.7 million in 2021, then plunged by 119.52% to -$1.3 million in 2022, then tumbled by 86.92% to -$2.4 million in 2023, then slumped by 313.95% to -$10.1 million in 2024, then soared by 63.69% to -$3.7 million in 2025.
• Business Quant data shows GCTK's EBITDA at -$3.7 million in Q4 2025, -$4.2 million in Q3 2025, and -$4.7 million in Q2 2025.